X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oritavancin (194) 194
index medicus (136) 136
humans (115) 115
vancomycin (96) 96
pharmacology & pharmacy (91) 91
microbiology (80) 80
infectious diseases (78) 78
dalbavancin (67) 67
anti-bacterial agents - pharmacology (66) 66
anti-bacterial agents - therapeutic use (59) 59
antibiotics (59) 59
single-dose oritavancin (57) 57
acute bacterial skin (56) 56
resistant staphylococcus-aureus (53) 53
in-vitro activity (49) 49
daptomycin (44) 44
telavancin (44) 44
glycopeptides - pharmacology (43) 43
staphylococcus-aureus (38) 38
microbial sensitivity tests (35) 35
complicated skin (34) 34
soft-tissue infections (34) 34
glycopeptides (32) 32
glycopeptides - therapeutic use (32) 32
infections (30) 30
linezolid (30) 30
staphylococcus aureus (30) 30
skin-structure infections (28) 28
animals (27) 27
gram-positive bacteria (27) 27
lipoglycopeptide (27) 27
skin diseases, bacterial - drug therapy (27) 27
bacteria (26) 26
gram-positive bacterial infections - drug therapy (26) 26
vancomycin - pharmacology (26) 26
anti-bacterial agents - administration & dosage (25) 25
skin (25) 25
anti-bacterial agents - adverse effects (24) 24
anti-bacterial agents - pharmacokinetics (24) 24
staphylococcus infections (22) 22
antimicrobial agents (21) 21
once-weekly dalbavancin (21) 21
tigecycline (21) 21
antibacterial agents (20) 20
health aspects (20) 20
internal medicine (20) 20
methicillin-resistant staphylococcus aureus (20) 20
teicoplanin - analogs & derivatives (20) 20
double-blind (19) 19
drug resistance (19) 19
gram-positive bacteria - drug effects (19) 19
mrsa (19) 19
drug resistance in microorganisms (18) 18
female (18) 18
infection (18) 18
staphylococcal infections - drug therapy (18) 18
teicoplanin (18) 18
anti-bacterial agents - chemistry (17) 17
drug therapy (17) 17
enterococcus-faecium (17) 17
gram-positive bacterial infections - microbiology (17) 17
pharmacokinetics (17) 17
pharmacology (17) 17
resistance (17) 17
staphylococcus aureus - drug effects (17) 17
tedizolid (17) 17
antibacterial activity (16) 16
glycopeptides - adverse effects (16) 16
glycopeptides - chemistry (16) 16
glycopeptides - pharmacokinetics (16) 16
gram-positive pathogens (16) 16
male (16) 16
methicillin-resistant staphylococcus aureus - drug effects (16) 16
vancomycin resistance (16) 16
care and treatment (15) 15
lipoglycopeptides (15) 15
research (15) 15
staphylococcus aureus infections (15) 15
therapy (15) 15
drug resistance, bacterial (14) 14
glycopeptide antibiotics (14) 14
immunology (14) 14
infectious disease (14) 14
biochemistry & molecular biology (13) 13
biosynthesis (13) 13
ceftaroline (13) 13
enterococci (13) 13
hospitals (13) 13
in-vitro (13) 13
ly333328 (13) 13
methicillin-resistant (13) 13
soft tissue infections - drug therapy (13) 13
staphylococcal infections - microbiology (13) 13
treatment outcome (13) 13
acute bacterial skin and skin structure infections (12) 12
analysis (12) 12
bacteremia (12) 12
bacterial infections (12) 12
clinical trials as topic (12) 12
glycopeptide (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Antimicrobial Agents, ISSN 0924-8579, 04/2019, Volume 53, Issue 4, pp. 429 - 434
Osteomyelitis remains difficult to treat, typically requiring a prolonged course of intravenous (i.v.) antibiotics. The optimal route and duration of... 
Osteomyelitis | Linezolid | Vancomycin | Oritavancin | Daptomycin | MRSA | DIAGNOSIS | INFECTIOUS DISEASES | INFECTIONS | PENETRATION | MICROBIOLOGY | FOOT | ACUTE BACTERIAL SKIN | PHARMACOLOGY & PHARMACY | BONE | SINGLE-DOSE ORITAVANCIN | Medical records | Health care industry | Care and treatment | Antibiotics
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 04/2012, Volume 54, pp. S229 - S229
Intact phagocytic effector function is fundamental to host defense against microbial pathogens. Concern has been raised regarding the potential that... 
Pathogens | Phagocytes | oritavancin | Antibiotics | Macrophages
Journal Article
Diagnostic Microbiology & Infectious Disease, ISSN 0732-8893, 06/2018, Volume 91, Issue 2, pp. 199 - 204
The in vitro activity of oritavancin was assessed against 44,715 gram-positive pathogens causing infections in European and United States (US) hospitals... 
Lipoglycopeptide | Oritavancin | Gram-positive cocci | LIPOGLYCOPEPTIDES | INFECTIOUS DISEASES | CARE-ASSOCIATED INFECTIONS | INVASIVE INFECTIONS | MICROBIOLOGY | VANCOMYCIN-RESISTANT ENTEROCOCCI | STREPTOCOCCI | ACUTE BACTERIAL SKIN | STAPHYLOCOCCI | US HOSPITALS | SINGLE-DOSE ORITAVANCIN | PATHOGENS | Medical centers | Antibacterial agents
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 08/2019, Volume 20, Issue 12, pp. 1493 - 1502
Journal Article
Infectious Diseases in Clinical Practice, ISSN 1056-9103, 05/2018, Volume 26, Issue 3, pp. 141 - 144
ABSTRACTNative vertebral osteomyelitis (NVO) is a difficult to treat infection often caused by hematogenous spread of bacteria to the bone, causing pain and... 
outpatient therapy | vertebral osteomyelitis | MRSA osteomyelitis | oritavancin
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2017, Volume 61, Issue 2, p. AAC.01968-16
Journal Article
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, ISSN 0066-4804, 07/2019, Volume 63, Issue 7
Weekly oritavancin plus ampicillin continuous infusion combination therapy was used to successfully treat a deep spine vancomycin-resistant Enterococcus... 
oritavancin | COMBINATIONS | ampicillin | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | STAPHYLOCOCCUS-AUREUS | vancomycin-resistant Enterococcus faecium | CHECKERBOARD | DAPTOMYCIN
Journal Article
The American Journal of Emergency Medicine, ISSN 0735-6757, 09/2019, p. 158442
Journal Article
Journal Article
Open Forum Infectious Diseases, ISSN 2328-8957, 2017, Volume 4, Issue 1, p. ofw274
Background. The objective of this analysis was to evaluate the efficacy and safety of oritavancin compared with vancomycin for patients with acute bacterial... 
ABSSSI | Vancomycin | Skin infections | Oritavancin | Long-acting lipoglycopeptides | INFECTIOUS DISEASES | oritavancin | EMERGENCY-DEPARTMENT | skin infections | GUIDELINES | long-acting lipoglycopeptides | vancomycin | SINGLE-DOSE ORITAVANCIN
Journal Article
Open Forum Infectious Diseases, ISSN 2328-8957, 06/2018, Volume 5, Issue 6, pp. 1 - 7
Background. Oritavancin is a lipoglycopeptide used in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. To characterize... 
ABSSSI | Registry | Skin infections | Oritavancin | registry | INFECTIOUS DISEASES | oritavancin | ANTIBIOTICS | IMPACT | ACUTE BACTERIAL SKIN | skin infections | MICROBIOLOGY | IMMUNOLOGY | SINGLE-DOSE ORITAVANCIN | STRUCTURE INFECTIONS
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 10/2015, Volume 35, Issue 10, pp. 935 - 948
Health care–associated infections, especially those caused by multidrug‐resistant gram‐positive organisms, such as methicillin‐resistant Staphylococcus aureus... 
oritavancin | infection | gram‐positive | lipoglycopeptide | dalbavancin | resistance | gram-positive | HERSHEY-MEDICAL-CENTER | ONCE-WEEKLY DALBAVANCIN | ECHO DOUBLE-RESONANCE | RESISTANT STAPHYLOCOCCUS-AUREUS | ACUTE BACTERIAL SKIN | SKIN-STRUCTURE INFECTIONS | SURVEILLANCE PROGRAM | ENTEROCOCCUS-FAECIUM | PHARMACOLOGY & PHARMACY | SINGLE-DOSE ORITAVANCIN | IN-VITRO ACTIVITY | Skin Diseases, Bacterial - microbiology | United States | Glycopeptides - administration & dosage | Humans | Half-Life | Skin Diseases, Bacterial - drug therapy | Teicoplanin - therapeutic use | Methicillin-Resistant Staphylococcus aureus | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Drug Interactions | Gram-Positive Bacterial Infections - microbiology | Teicoplanin - pharmacology | Anti-Bacterial Agents - adverse effects | Teicoplanin - analogs & derivatives | Vancomycin Resistance | Glycopeptides - adverse effects | Cross Infection - drug therapy | Glycopeptides - therapeutic use | Randomized Controlled Trials as Topic | Teicoplanin - adverse effects | Teicoplanin - administration & dosage | Animals | Cross Infection - microbiology | Anti-Bacterial Agents - pharmacology | Glycopeptides - pharmacology | Gram-Positive Bacterial Infections - drug therapy | Anti-Bacterial Agents - administration & dosage | Staphylococcus infections | FDA approval
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 23, pp. 2180 - 2190
Journal Article